Some healthcare shares from ASX listed companies have been on the run, surging even when the broader S&P/ASX All Ordinaries Index (ASX: XAO) is only marginally up. High growth stocks from such growing companies to invest in are
Orthocell Limited (ASX: OCC)
Orthocell Limited (ASX: OCC) continues its international expansion of its Remplir™ nerve repair device with the appointment of Device Technologies Asia as its exclusive distributor in Singapore. This move follows the device's successful launch and growing sales in Australia and New Zealand, and the company now plans to replicate this success in Singapore. Device Technologies Asia, which already has strong relationships with key surgeons and healthcare centers in Singapore, will oversee the marketing, promotion, and distribution of Remplir. The market launch is slated for Q1 2025, and with approximately $35 million in cash reserves, Orthocell is well-positioned to fund this expansion and drive adoption in the region. The strategic market entry into Singapore is significant, as it offers access not only to a high-quality medical market but also serves as a gateway to other ASEAN markets, with the global nerve repair market valued at over $3.5 billion.
Orthocell is also preparing for the US launch of Remplir™ in early 2025. The company recently appointed two key executives to lead the market introduction of the product in the United States. Both executives bring over 19 years of experience in the US nerve repair sector, having previously worked with Axogen, a leading company in nerve repair products. With an anticipated US market approval and the expected clearance of Remplir's 510(k) application by the end of Q4 2024, Orthocell is preparing for rapid sales growth in the US, a market worth $1.6 billion. The company has been actively engaging with US surgeons and research institutions to prepare for the launch.
To fund its expansion plans, Orthocell successfully completed a $17 million placement in October 2024. This capital raise, supported by both new and existing institutional investors, will be used to accelerate the global commercialization of Remplir™ and Striate+™. The funds will be directed toward scaling up manufacturing, enhancing cost efficiencies, expanding the sales and marketing efforts, and covering operational expenses related to the US launch and other markets like Southeast Asia, Canada, and the EU/UK. With its strong balance sheet and no debt, Orthocell is well-positioned to continue its global growth trajectory in 2025.
PYC Therapeutics Limited (ASX: PYC)
PYC Therapeutics continues to demonstrate significant progress in the development of precision RNA therapies targeting unmet medical needs, particularly in irreversible and progressive diseases. The company's lead investigational drug candidate has shown encouraging results in Phase 1/2 trials, improving vision in patients with a previously untreatable blinding eye disease. These outcomes, achieved without serious adverse events, mark a groundbreaking advancement as the first therapy for this condition to enter human trials. Additionally, PYC’s platform has validated its precision medicine approach, progressing another RNA-based therapy for a different blinding eye disease into clinical trials.
The company remains well-capitalized, securing A$75 million (USD$50 million) through a fully subscribed rights issue, funding pipeline progression through key clinical milestones. With orphan drug designations for two indications (RP11 and ADOA) and a rare pediatric disease designation (ADOA) from the FDA, PYC’s regulatory achievements highlight the strong differentiation and potential of its programs. Looking ahead to 2025, PYC anticipates advancing high-value assets into late-stage (registrational) trials, reporting critical safety and efficacy data, and initiating a first-in-human trial for a candidate targeting polycystic kidney disease—addressing millions of patients worldwide. IND-enabling studies for its Phelan-McDermid Syndrome candidate are also expected, continuing its momentum of delivering high-impact candidates to the clinic.
Operationally, PYC maintains a disciplined and efficient model, achieving substantial programmatic progress with an annual net expenditure of A$43 million (USD$28 million) in FY2024. This resource optimization reflects effective shareholder capital deployment, with significant value added to its pipeline assets. The company’s ability to secure additional funding through strategic licensing, asset sales, or equity markets ensures continued growth. PYC is poised to have three clinical-stage assets by late 2025, with a fourth in preclinical development. This expanding pipeline underscores the company’s potential for long-term value creation in high-probability programs with accelerated clinical timelines. Leadership continues to prioritize talent acquisition, bolstering organizational capabilities to support this growth trajectory.
As demand for precision therapies with strong clinical validation rises, PYC is among the best growth stocks to buy now, as it is uniquely positioned to capitalize on its platform's potential, delivering transformative solutions for patients and robust returns for stakeholders.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.